期刊文献+

二氟甲基鸟氨酸对T淋巴瘤Jurkat细胞生长的影响 被引量:3

Difluoromethylornithine suppresses growth and improves apoptosis of human leukemia Jurkat cells
下载PDF
导出
摘要 目的研究二氟甲基鸟氨酸(difluromethylornithine,DFMO)对人T淋巴瘤Jurkat细胞的影响及其作用机制,为探讨DFMO能否用于治疗人白血病提供实验依据。方法DFMO(0~10mmol/L)处理人T淋巴瘤Jurkat细胞24~72h后,MTS法检测细胞的存活率,化学分析法检测精胺氧化酶(spermine oxidase,SMO)和乙酰多胺氧化酶(acetylpolyamine oxidase,APAO)活性,DNA片段化分析检测细胞凋亡,荧光染料法检测细胞线粒体膜电位变化,Western blot法检测细胞内Bax含量,分光光度法检测caspase-3酶活性。结果DFMO处理细胞能显著抑制Jurkat细胞的生长(P<0.01),抑制率随药物浓度的增加和作用时间的延长而加大,DFMO浓度为10mmol/L时,24h抑制率为33%,48h抑制率为38%,72h抑制率为49%。DFMO处理可导致Jurkat细胞DNA片段化,促进Bax由细胞质向线粒体转移,细胞内caspase-3活性增加(增加46%,P<0.05),并伴有线粒体膜电位的显著降低,DFMO浓液为2和5mmol/L时,分别降低29%和53%(P<0.01)。DFMO还能诱导细胞内SMO活性(增加1.1倍,P<0.05)但对APAO的活性无诱导性影响。结论DFMO对人T淋巴瘤Jurkat细胞具有生长抑制和诱导凋亡的作用。 Objective To investigate whether difluromethylornithine (DFMO) can be used in the treatment of human leukemia. Methods The cell proliferation was detected by MTS [3-(4,5-dimethylthiazol- 2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) ] assay after treatment of human lymphocyte Jurkat cells by DFMO (0 to 10 retool/L) for 24 to 72 h. Enzyme activity of spermine oxidase (SMO) and acetylpolyamine oxidase (PAO) was determined by chemiluminesence assay. DNA fragmentation assay was used to evaluate cell apoptosis. Fluorescent dye assay was performed to determine the changes in mitochondrial membrane potential. Western blotting was used to determine Bax content. Casepase-3 enzyme activity was measured by spectrophotometric method. Results DFMO treatment inhibited the proliferation of Jurkat cells significantly in a dosage- and time-dependent manner (P 〈 0.01 ). When DFMO concentration was 10 mmol/L, the inhibitory rate for cell growth was 33% in 24 h, 38% in 48 h and 49% in 72 h respectively. DFMO treatment resulted in DNA fragmentation, promoted translocation of Bax from the cytoplasma to the mitochondria and increased caspase-3 activity by 46% ( P 〈 0. 05 ) accompanied by a significant reduction in the mitochondrial membrane potential in Jurkat cells, reducing 29% at 2 mmol/L DFMO and 53% at 5 mmol/L DFMO (P 〈0. 01 ). DFMO promoted the activity of SMO by 1.1-fold (P 〈0.05) but no inducible effect on PAO activity in Jurkat cells. Conclusion DFMO can inhibit cell growth and induce apoptosis in human leukemia Jurkat cells.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2010年第6期593-596,共4页 Journal of Third Military Medical University
基金 Supported by the National Natural Science Foundation of China(30772590) the Key Project of Science Foundation of Department of Education of Hubei Province(D200713003)
关键词 二氟甲基鸟氨酸 T淋巴细胞 JURKAT细胞 细胞凋亡 生长抑制物 difluromethylornithine T-Lymphocytes Jurkat cells apoptosis growth inhibitors
  • 相关文献

参考文献11

  • 1Babbar N, Murray-Stewart T, Casero R A Jr. Inflammation and polyamine catabolism: the good, the bad and the ugly [ J ]. Biochem Soc Trans, 2007, 35 ( Pt 2) : 300 - 304.
  • 2Moinard C, Cynober L, de-Bandt J P. Polyamines: metabolism and implications in human diseases[J]. Clin Nutr, 2005, 24(2) : 184 - 197.
  • 3Wang Y, Casero R A Jr. Mammalian polyarnine catabolism: a therapeutic target, a pathological problem, or both? [J]. J Biochem (Tokyo), 2006, 139(1): 17-25.
  • 4Casero R A Jr, Marton L J. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases[ J]. Nat Rev Drug Discov, 2007, 6 (5) : 373 - 390.
  • 5Shantz L M, Levin V A. Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential [ J ]. Amino Acids, 2007, 33 (2) : 213 -223.
  • 6Wallace H M, Fraser A V, Hughes A. A perspective of polyamine metabolism[J]. Bioehem J, 2003, 376(Pt 1) : 1 - 14.
  • 7Simoneau A R, Gerner E W, Nagle R, et al. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: resuits of a year-long phase IIb randomized placebo-controlled chemoprevention trial[ J ]. Cancer Epidemiol Biomarkers Prey, 2008, 17 (2) : 292 - 299.
  • 8Jiang X, Wang X. Cytochrome C-mediated apoptosis[ J]. Annu Rev Biochem, 2004, 73: 87- 106.
  • 9Wang Y, Hacker A, Murray-Stewart T, et al. Induction of human spermine oxidase SMO ( PAOhl ) is regulated at the levels of new mRNA synthesis, mRNA stabilization and newly synlhesized protein [J]. BiochemJ, 2005,386(Pt3): 543-547.
  • 10Wang Y, Hacker A, Murray-Stewart T, et al. Properties of recombinant human N1-acetylpolyamine oxidase (hPAO) : potential role in determining drug sensitivity [ J ]. Cancer Chemnther Pharmacol, 2005, 56(1) : 83 -90.

同被引文献37

  • 1Beck R, Verrax J, Gonze T, et al. Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death [ J ]. Biochem Pharmacol, 2009, 77 (3) : 375 - 383.
  • 2Chan C T, Paulmurugan R, Gheysens O S, et al. Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects [ J ]. Cancer Res, 2008, 68( 1 ) : 216 -226.
  • 3Chatteljee M, Jain S, Stuhmer T, et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival [J]. Blood, 2007, 109(2) : 720 -728.
  • 4Kurokawa M, Zhao C, Reya T, et al. Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias [J]. Mol Cell Biol, 2008, 28 ( 17 ) : 5494 - 5506.
  • 5Wu L X, Xu J H, Zhang K Z, et al. Disruption of the Bcr-Ab1/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin [ J ]. Leukemia, 2008, 22 ( 7 ) : 1402 - 1409.
  • 6Peng C, Brain J, Hu Y, et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells[J].Blood, 2007, 110(2) : 678 -685.
  • 7Lu Z, Jin Y, Qiu L, et al. Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T3151 mutation [ J ]. Cancer Lett, 2010, 290(2) : 182 -191.
  • 8Livak K J, Schmittgen T D. Analysis of relative gene expression data using real-time quantitative PCR and the 2 [-Delta Delta C (T)] Method[J]. Methods, 2001, 25(4) : 402 - 408.
  • 9Luo Q, Kang Q, Song w x, et al. Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing [J].Gene, 2007, 395 (1/2) : 160 - 169.
  • 10Larizza L, Magnani I, Beghini A. The Kasumi-I cell line: at (8; 21 )-kit mutant model for acute myeloid leukemia[J].Leuk Lymphoma, 2005, 46(2) : 247 -255.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部